A 2026 clinical guide to prescribing GLP-1 medications for weight management: approved agents, dosing, side effects, contraindications and program setup.
How to build a medical weight-loss program: choosing your business model, clinical protocols, staffing to scope, compliance, pricing and team training.
GLP-1 prior authorization for prescribers: why PAs get denied, the documentation payers want, step therapy, Medicare’s GLP-1 Bridge, and appeals that work.
Compounded tirzepatide in 2026: where the FDA rules now stand, the documented safety signal, prescriber liability, and how to transition patients safely.
Compounded semaglutide in 2026: the shortage is resolved, 503B bulk compounding is out, and an FDA rule would end it for good. What prescribers can do now.
GLP-1 and anesthesia: current multisociety guidance says most patients can continue before surgery. Risk tiers, liquid-diet rules and gastric ultrasound
What the GLP-1 thyroid boxed warning and pancreatitis signal actually mean: how to screen for MTC and MEN2, what not to monitor, and how to document consent.
Preventing muscle loss on GLP-1 therapy: how much lean mass patients lose, protein targets, prescribing resistance training and monitoring body composition.
A clinical guide to GLP-1 weight-loss plateaus: separate an expected stall from true non-response, confirm adherence, optimize the dose, and when to switch.
Prevent and manage GLP-1 GI side effects: labeled nausea rates, counseling that works, titration adjustments, and the red-flag symptoms that need a work-up.
Terms and conditions apply. Offer expires October 31.